Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Fayez Kheir

Pulmonary Disease Boston, MA Medical Doctor

NPI 1881867935 CMS profile 1157282

55 Fruit St, Ste 201, Boston, MA 02114

Open in the dashboard

General payments

$20,548

62 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Fayez Kheir of Boston, MA is reported in the CMS Open Payments database as having received $20,548 across 62 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,679 4
2024 General $5,203 6
2023 General $233 3
2022 General $966 3
2021 General $7,164 21
2020 General $1,251 10
2019 General $4,053 15

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Fayez Kheir
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Fayez Kheir were reported at $1,679. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Fayez Kheir Pulmonary Disease median Middle half National median
2019 $4,053 $377 $109–$1,340 $163
2020 $1,251 $230 $56–$907 $114
2021 $7,164 $269 $68–$1,072 $132
2022 $966 $390 $100–$1,457 $149
2023 $233 $419 $114–$1,659 $160
2024 $5,203 $476 $123–$1,818 $164
2025 $1,679 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pinnacle Biologics, Inc $6,228 13 payments
  2. Boston Scientific Corporation $6,147 8 payments
  3. Veran Medical Technologies, Inc. $1,558 3 payments
  4. Intuitive Surgical, Inc. $1,548 8 payments
  5. Gyrus ACMI, Inc. $1,412 2 payments
  6. Pulmonx Corporation $1,250 10 payments
  7. Ambu A/S $750 1 payment
  8. PENTAX of America, Inc. $500 1 payment
  9. Galvanize Therapeutics, Inc $400 1 payment
  10. Medtronic, Inc. $379 2 payments
  11. Other $375 13 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $8,498 8 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $5,350 3 payments
  3. Travel and Lodging $4,611 16 payments
  4. Food and Beverage $2,066 34 payments
  5. Education $23 1 payment
Products named General payments · program years 2019–2025
  1. Photofrin $6,228 13 payments
  2. GENERAL - THERAPIES $3,268 2 payments
  3. GENERAL PULMONARY $1,600 1 payment
  4. Spin $1,558 3 payments
  5. Da Vinci Surgical System $1,548 8 payments
  6. MEDICAL CONTROL UNIT FOR ENDOSURGERY UCES-4 $1,412 2 payments
  7. GENERAL - PULMONARY $800 1 payment
  8. Pulmonx Endobronchial Valve EBV $654 5 payments
  9. ZEPHYR ENDOBRONCHIAL VALVE $596 5 payments
  10. ALIYA SYSTEM $400 1 payment
  11. Other $1,816 31 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 53 billing codes

Paid by Medicare

$45,155

Medicare's payments for the services billed

Medicare patients

167

Average age 71

Services billed

490

76 women, 91 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 49%
COPD 49%
Arthritis 49%
Chronic kidney disease 38%
Cancer 38%
Atrial fibrillation 37%
Heart failure 36%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

62 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record